Cadila Launches Adalimumab Biosimilar, Cadalimab in India

Country: INDIA | Region: ASIA & SOUTH PACIFIC | Type: Drug Launch | Keywords: #adalimumab #biosimilar #cadalimab #cadila #humira


PRICENTRIC BRIEF:
  • Cadila Pharmaceuticals has announced the launch of its adalimumab biosimilar, Cadalimab, referencing AbbVie’s blockbuster Humira, in India
  • Cadalimab is available in 40mg/0.8ml injection and has shown to lead to a significant reduction in signs and symptoms of rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis
  • Cadalimab is the fourth biosimilar from Cadila launched in the last 4 months, following Bevaro (bevacizumab), Ritucad (rituximab), and NuPTH (teriparatide), which are intended for the treatment of cancer and osteoporosis

THE DETAILS

AHMEDABAD, India – Cadila Pharmaceuticals has announced the launch of its adalimumab biosimilar, Cadalimab, referencing AbbVie’s blockbuster Humira, in India.

As with the reference biologic, Cadalimab is used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis. Cadalimab is available in 40mg/0.8ml injection and has shown to lead to a significant reduction in signs and symptoms of rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis.

Amit Ajmera, Vice President, Cadila, said, “Around 7 million people in India suffer from rheumatoid arthritis, while 0.44-2.8% of people in India suffer from psoriasis. While these are not life-threatening, psoriasis and RA can be painful to live with. With the launch of Cadalimab, we want to reach these patients with a cost-effective solution and give them a chance at a better life.”

O.P. Singh, President, Sale and Marketing, Cadila, added, “With the launch of every product, we strengthen our core philosophy of providing quality medicines to all. Cadalimab comes in an easy pre-filled syringe, which makes it easy to use for every patient and provides them relief from disorders such as arthritis and psoriasis. We are on a journey to expand treatment options with affordable biosimilars.”

Cadalimab is the fourth biosimilar from Cadila launched in the last 4 months, following Bevaro (bevacizumab), Ritucad (rituximab), and NuPTH (teriparatide), which are intended for the treatment of cancer and osteoporosis.

Learn more about Pricentric ONE and our Global Pricing Solutions!

Contact us with your questions and global pricing needs, and an expert will follow up shortly.